Investment in research and development for new and improved
treatments is contributing to market growth.
WILMINGTON, Del., Aug. 1, 2024
/PRNewswire/ -- The Non-Hodgkin's lymphoma therapeutics market was
projected to attain US$ 8.0 billion
in 2023. It is likely to garner an 8.0% CAGR from
2024 to 2034, and by 2034, the market is expected to
attain US$ 18.6 billion.
Existing treatments may not be effective for all patients, creating
a demand for new therapies. There is a shift towards personalized
medicine with therapies targeting specific cancer cells or
molecular pathways, such as monoclonal antibodies and kinase
inhibitors.
![Transparency Market Research Logo Transparency Market Research Logo](https://mma.prnewswire.com/media/1682871/TMR_Logo_Logo.jpg)
The use of immune checkpoint inhibitors and CAR-T cell therapies
is becoming more prevalent, offering new hope for NHL patients.
Combining different therapeutic approaches (e.g., chemotherapy with
targeted therapy) is gaining traction to improve efficacy and
reduce resistance. Advances in biomarker identification are
enhancing the ability to diagnose NHL early and tailor treatments
to individual patients. Increased access to healthcare in emerging
markets is expanding the availability of NHL therapies.
Download Sample of the Report:
https://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=2668
There is potential for significant growth in the market with the
development of new drugs and therapies that address unmet needs.
Initiatives that support patients through their treatment journey
can enhance patient adherence and improve outcomes. Improved
awareness and screening programs lead to earlier detection and
diagnosis of NHL, increasing the demand for therapeutic options.
Better understanding of the genetic basis of NHL enables the
development of targeted therapies that are more effective and have
fewer side effects.
Non-Hodgkin's Lymphoma Therapeutics Market Report
Scope:
Report
Coverage
|
Details
|
Forecast
Period
|
2024-2034
|
Base
Year
|
2020-2022
|
Size in 2023
|
US$ 8.0 Bn
|
Forecast (Value) in
2034
|
US$ 18.6 Bn
|
Growth Rate
(CAGR)
|
8.0 %
|
No. of
Pages
|
145
Pages
|
Segments
covered
|
By Treatment Therapy,
By Indication Type, By Route of Administration, By Region, By
End-user
|
Non-Hodgkin's Lymphoma Therapeutics Market: Key
Players
The non-hodgkin's lymphoma therapeutics market is characterized
by intense competition among pharmaceutical and biotechnology
companies, driven by the demand for innovative and effective
treatments. The following companies are well known participants in
the non-hodgkin's lymphoma therapeutics market:
- Mylan N.V.
- Teva Pharmaceutical Industries Ltd.
- Sanofi S.A.
- Pfizer Inc.
- GSK plc
- Novartis AG
- Bayer AG
- Eli Lilly and Company
- Merck & Co. Inc.
- AbbVie Inc.
- AstraZeneca plc
- Johnson & Johnson Pvt. Ltd.
Key Developments
- In 2021, Kyowa Kirin Co., Ltd., in collaboration with MEI
Pharma, Inc., announced the completion of patient
enrollment for the Follicular Lymphoma Primary Efficacy
Population in their global Phase 2 TIDAL study.
- In the same year, Bristol-Myers Squibb Company announced
that the U.S. FDA had approved their CAR-T cell therapy,
Breyanzi, for the treatment of large B-cell lymphoma in
patients who have relapsed or not responded after at least two
other systemic treatments.
Key Findings of the Market Report
- Innovations in imaging and diagnostic technologies, such as PET
and MRI scans, facilitate more accurate disease staging and
treatment planning.
- The integration of digital health technologies, such as
telemedicine and mobile health apps, enhances patient monitoring
and management, leading to better outcomes.
- Personalized treatment plans and patient-centric care models
are gaining prominence, improving patient experiences and adherence
to therapies.
- There is a growing emphasis on managing long-term therapy
effects and improving the quality of life for patients through
supportive care and symptom management.
Market Trends for Non-Hodgkin's Lymphoma Therapeutics
- By treatment therapy, the imunotherapy segment is expected to
boost the growth of the non-hodgkin's lymphoma therapeutics market.
Immunotherapy includes advanced treatments such as CAR-T cell
therapy, immune checkpoint inhibitors, and monoclonal antibodies,
which have shown significant promise in treating various types of
NHL. These innovations offer new hope for patients who do not
respond well to traditional therapies.
- In terms of indication type, the B-cell lymphomas segment is
anticipated to augment the growth of the non-hodgkin's lymphoma
therapeutics market. B-cell lymphomas are more common compared to
T-cell lymphomas, which translates to a larger patient population
and a higher demand for therapeutic options. Significant
advancements in treatments for B-cell lymphomas, such as CAR-T cell
therapies (e.g., Kymriah and Yescarta) and novel monoclonal
antibodies (e.g., Rituximab), have improved patient outcomes and
increased market growth.
Explore Sample of the Report:
https://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=2668
Global Market for Non-Hodgkin's Lymphoma Therapeutics:
Regional Outlook
North America
- North America has a high
incidence and prevalence of NHL, leading to a significant patient
population and increased demand for effective therapeutic
options.
- The region boasts a well-developed healthcare infrastructure,
including state-of-the-art medical facilities, advanced diagnostic
tools, and cutting-edge treatment options, which supports the
growth of the NHL therapeutics market.
Asia Pacific
- The introduction and expansion of new treatments, including
targeted therapies and immunotherapies, are becoming more
accessible in Asia Pacific
countries, driving market growth.
- Growing awareness about NHL and improvements in diagnostic
capabilities are leading to earlier diagnosis and treatment,
boosting the demand for therapeutic solutions.
Non-Hodgkin's Lymphoma Therapeutics Market
Segmentation
Treatment Therapy
- Chemotherapy
- Targeted Therapy
- Immunotherapy
- Others (Radiation Therapy, etc.)
Indication Type
- B-Cell Lymphomas
- T-Cell Lymphomas
Route of Administration
End User
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
Region
- North America
- Latin America
- Europe
- Asia Pacific
- Middle East &
Africa
Buy this Premium Research Report:
https://www.transparencymarketresearch.com/checkout.php?rep_id=2668<ype=S
More Trending Report by Transparency Market Research:
- Vaccines Market: The global vaccines market is
projected to expand at a CAGR of 4.2% during the forecast
period from 2023 to 2031
- Laser Capture Microdissection Market: Market for
Laser Capture Microdissection is expected to grow at a CAGR
of 10.7% from 2024 to 2034 and reach US$
739.6 Mn by the end of 2034
- Electronic Health Records Market likely to surpass
USD 50 Bn by 2031, expanding at a
5% CAGR
- IV Bags Market Predicted to Reach USD 1.5 billion by 2032, Expanding at a CAGR
of 5.8%
About Transparency Market Research
Transparency Market Research, a global market
research company registered at Wilmington, Delaware, United States, provides custom research and
consulting services. Our exclusive blend of quantitative
forecasting and trends analysis provides forward-looking insights
for thousands of decision makers. Our experienced team of Analysts,
Researchers, and Consultants use proprietary data sources and
various tools & techniques to gather and analyses
information.
Our data repository is continuously updated and revised by a
team of research experts, so that it always reflects the latest
trends and information. With a broad research and analysis
capability, Transparency Market Research employs rigorous primary
and secondary research techniques in developing distinctive data
sets and research material for business reports.
Contact:
Transparency Market Research Inc.
CORPORATE HEADQUARTER
DOWNTOWN,
1000 N. West Street,
Suite 1200, Wilmington, Delaware
19801 USA
Tel: +1-518-618-1030
USA – Canada Toll Free:
866-552-3453
Website: https://www.transparencymarketresearch.com
Email: sales@transparencymarketresearch.com
Follow
Us: LinkedIn| Twitter| Blog | YouTube
Logo:
https://mma.prnewswire.com/media/1682871/TMR_Logo_Logo.jpg
View original
content:https://www.prnewswire.com/news-releases/non-hodgkins-lymphoma-therapeutics-market-to-reach-usd-18-6-billion-by-2034-fuelled-by-new-drugs-and-targeted-therapies--latest-report-by-tmr-302212299.html
SOURCE Transparency Market Research